Study objectives included determining demographic, phenotypic, diagnostic and treatment features, and outcomes of all patients who underwent serum/CSF myelin oligodendrocyte glycoprotein (MOG) antibody testing.
No takes yet. Share an insight, caveat, or question.
Burton et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: